Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 10/20 | 0.76 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.48 |
| ▸ | CCR6 | P51684 | 7/20 | 0.45 |
| ▸ | LIN28A | Q9H9Z2 | 2/20 | 0.39 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3880456 | 0.86 | CXCR2 (1.00) | CXCR2CXCR1CCR6 | |
| SCHEMBL3880246 | 0.85 | CXCR2 (0.79) | CXCR2CXCR1CCR6CLCN2 | |
| SCHEMBL3882155 | 0.84 | CXCR2 (0.77) | CXCR2CXCR1CCR6 | |
| SCHEMBL3881706 | 0.81 | CXCR2 (0.73) | CXCR2CXCR1CCR6 | |
| SCHEMBL3880212 | 0.81 | CXCR2 (0.73) | CXCR2CXCR1CCR6 | |
| SCHEMBL3882266 | 0.81 | CXCR2 (0.66) | CXCR2CXCR1CCR6LIN28ACLCN2 | |
| SCHEMBL3888680 | 0.80 | CXCR2 (0.65) | CXCR2CXCR1CCR6 | |
| SCHEMBL3882244 | 0.79 | CXCR2 (0.69) | CXCR2CXCR1CCR6CLCN2 | |
| SCHEMBL6138369 | 0.77 | CXCR2 (0.47) | CXCR2CCR6 | |
| SCHEMBL5711802 | 0.75 | CXCR2 (0.52) | CXCR2CXCR1CCR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1357909-B1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20060084661-A1 | IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2006-04-20 | — | — | US | disclosed |
| EP-1357909-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2006-01-04 | — | — | EP | disclosed |
| US-20040132694-A1 | Il-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2004-07-08 | — | — | US | disclosed |
| EP-1357909-A1 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002067919-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132694-A1 | Il-8 receptor antagonists | CXCL8, CCR8, TLR8 | CXCR2 16/4885CXCR1 14/4885CCR6 50/4885 |
| US-20060084661-A1 | IL-8 receptor antagonists | CXCL8, CCR8, TLR8 | CXCR2 16/4885CXCR1 14/4885CCR6 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.